Usa city Sanofi covid-19 vaccine DNA infection Usa city Sanofi

Sanofi and GSK partner to develop Covid-19 vaccine

Reading now: 893
www.pharmaceutical-technology.com

Sanofi and GlaxoSmithKline (GSK) have signed a letter of intent for a partnership focused on developing an adjuvanted vaccine for Covid-19.

While Sanofi and GSK are also working separately to enable vaccines for the viral infection, the latest alliance is intended to combine their respective technologies.

As part of the collaboration, Sanofi will provide its S-protein Covid-19 antigen based on recombinant DNA technology, used to generate an ‘exact genetic match’ to proteins present on the SARS-CoV-2’s surface.

Furthermore, Sanofi combined the DNA sequence encoding the antigen with the DNA of the baculovirus expression platform, which supported the company’s licensed recombinant influenza product in the US.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA